sanofi

HμREL, Sanofi collaborate

Wednesday, October 2, 2013 01:12 PM

HμREL, a provider of advanced tissue constructs and microfluidic cell-based assay platforms for preclinical drug development, has entered into a multi-phase R&D collaboration with Sanofi U.S.

More... »

Tom Shepherd named CEO of Bioaster

Monday, September 16, 2013 08:47 AM

Dr. Tom Shepherd has been appointed chief executive officer of Bioaster, a Technology Research Institute focused on infectious diseases and microbiology

More... »

Sanofi, Pozen ink exclusive license agreement

Friday, September 6, 2013 02:59 PM

Sanofi and Pozen, a pharmaceutical company specializing in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization, have announced an exclusive license agreement for commercialization of Pozen's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet (PA), PA8140 and PA32540. Sanofi will have exclusive rights to commercialize all PA combinations that contain 325mg or less of enteric-coated aspirin in the U.S. Pozen will receive an upfront payment of $15 million and will be eligible for pre-commercial milestone payments of up to $20 million and other future milestone payments and royalties on product sales. 

More... »

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »

EFPIA, PhRMA release joint principles for responsible data sharing

Wednesday, July 24, 2013 01:41 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) have endorsed joint “Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers.”

More... »

InnovoCommerce, SAFE-BioPharma collaborate

Friday, June 28, 2013 02:02 PM

The global SAFE-BioPharma digital identity and signature standard is being incorporated into the InnovoCommerce eClinical product suite used by pharmaceutical companies for their enterprise and investigator portal initiatives. InnovoCommerce is a source of eClinical collaboration products and solutions. It also has joined SAFE-BioPharma Association’s Vendor Partner program.

More... »

Astellas Pharma joins SAFE-BioPharma

Friday, June 21, 2013 01:21 PM

Astellas Pharma has joined the SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the global SAFE-BioPharma digital identity and signature standard. As a member, Astellas is able to utilize the SAFE-BioPharma standard. It is the first Japanese pharmaceutical company to become a member.

More... »

Curie-Cancer, Sanofi collaborate

Wednesday, June 19, 2013 01:42 PM

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Carnot Institute, have established a three-year research collaboration to identify new therapeutic targets for developing treatments for ovarian cancer.

More... »

Sanofi discontinues development of two investigational compounds

Tuesday, June 4, 2013 10:00 AM

Sanofi, a global healthcare company, announced topline results of two phase III clinical studies of investigational compounds iniparib and otamixaban and, as a result, has announced it will discontinue both programs.

More... »

Wierman appointed Theorem vice president of biopharmaceutical development

Monday, May 13, 2013 08:00 AM

Theorem Clinical Research, a King of Prussia, Penn.-based, mid-sized provider of comprehensive clinical research and development services, has appointed Connie Wierman as vice president of biopharmaceutical development. Wierman leads the company’s oncology therapeutic focus for the biopharmaceutical business unit.

More... »